GlassScriptPhysician profile
Joseph C Perez
NPI 1750390605
$8,106.14
in general payments reported to CMS, 2019-2025
25 companies · $1,776 in 2025
The $1,776 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $637 · 2021: $872 · 2022: $1,398 · 2023: $1,305 · 2024: $1,146 · 2025: $1,776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,193 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,193.17 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,998.65 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $1,177.78 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,065.46 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Grifols USA, LLC | $693.76 | 2019-2025 | Xembify |
| Regeneron Healthcare Solutions, INC. | $475.81 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $412.03 | 2020-2025 | Cuvitru |
| Pfizer INC. | $363.71 | 2019-2025 | |
| Kaleo, INC. | $227.99 | 2019-2024 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.64 | 2019-2022 | |
| Amgen INC. | $188.51 | 2020-2025 | |
| Optinose US, INC. | $178.78 | 2019-2025 | |
| Shire North American Group INC | $167.61 | 2019 | |
| Gc Biopharma USA, INC. | $164.16 | 2024-2025 | Alyglo, Alyglo |
| Ars Pharmaceuticals Operations, INC. | $152.07 | 2025 | Neffy |
| Csl Behring | $147.86 | 2020-2025 | Hizentra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $136.73 | 2019-2023 | Odactra |
| Organon LLC | $124.89 | 2025 | Vtama |
| Teva Pharmaceuticals USA, INC. | $53.78 | 2021 | |
| Octapharma USA, INC. | $52.70 | 2020-2022 | |
| Hospira, INC. | $48.99 | 2024-2025 | |
| Genentech USA, INC. | $27.57 | 2025 | Xolair |
| Aytu Biopharma, INC. | $15.32 | 2021 | |
| Phadia US INC. | $14.89 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.51 | 2021 | |
| Merck Sharp & Dohme LLC | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.